| 000 | 01667 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250516122135.0 | ||
| 264 | 0 | _c20130429 | |
| 008 | 201304s 0 0 eng d | ||
| 022 | _a1744-7666 | ||
| 024 | 7 |
_a10.1517/14656566.2012.744821 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEaddy, Michael | |
| 245 | 0 | 0 |
_aEstablishing the clinical and economic benefits of adherence to 5-alpha reductase inhibitors in benign prostatic hyperplasia: an assessment of Medicare and Medicaid patients. _h[electronic resource] |
| 260 |
_bExpert opinion on pharmacotherapy _cDec 2012 |
||
| 300 |
_a2593-600 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_a5-alpha Reductase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aCost Savings |
| 650 | 0 | 4 | _aDatabases, Factual |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHealth Care Costs |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMedicaid |
| 650 | 0 | 4 | _aMedicare |
| 650 | 0 | 4 | _aMedication Adherence |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 |
_aProstate _xdrug effects |
| 650 | 0 | 4 |
_aProstatic Hyperplasia _xdrug therapy |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 |
_aUrinary Retention _xeconomics |
| 700 | 1 | _aKruep, Eric | |
| 700 | 1 | _aLunacsek, Orsolya | |
| 700 | 1 | _aGoodwin, Bridget | |
| 773 | 0 |
_tExpert opinion on pharmacotherapy _gvol. 13 _gno. 18 _gp. 2593-600 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/14656566.2012.744821 _zAvailable from publisher's website |
| 999 |
_c22275372 _d22275372 |
||